EKF Diagnostics Investor Announcements


EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Standard form for notification of major holdings. 

EKF Diagnostics Holdings plc (AIM: EKF) announces that on 24 May 2019, the Company was notified by  Adam Reynolds, Non-executive Director, that he has today sold 400,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares").

EKF Diagnostics Holdings notes the announcement by Renalytix AI plcthat on 26 April 2019 EKF Diagnostics plc acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.

EKF Diagnostics confirms that the Annual Report and Accounts for the year ended 31 December 2018 and the Notice of the Annual General Meeting contained therein are available.

13th Mar 2019

EKF Diagnostics Holdings plc announces its final results for the year ended 31 December 2018.

8th Mar 2019

EKF announces that it will release its preliminary results for the year ended 31 December 2018 on Wednesday 13 March 2019.

EKF Diagnostics announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.

EKF announces the full launch of the McKesson Consult® Hb analyzer in the US  in February.

16th Jan 2019

EKF Diagnostics provides shareholders with the following update on current trading. 

EKF Diagnostics Holdings plc announces that, further to the announcement on 1 November regarding its planned appointment of a new nominated adviser following the admission of Renalytix AI PLC (“RenalytixAI”) to trading on AIM, the boards of EKF and RenalytixAI have now agreed a different resolution to the requirement for one of the two companies to appoint a new nominated adviser.